IRWD Positive Sentiment
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Key Takeaway: Ironwood Pharmaceuticals will present real-world data at Digestive Disease Week 2025. The focus will be on the adoption of new diagnosis codes for short bowel syndrome patients reliant on parenteral support. This presentation aims to improve patient care and understanding of the condition.
Price reaction · baseline $0.7049 (2025-04-21 close) · hit after-hours · 2 other IRWD headline(s) in the window, move may be shared
day 0 close · peak
+2.1%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals is presenting real-world data.
- The presentation focuses on new diagnosis codes for short bowel syndrome.
- This could enhance understanding and treatment for patients dependent on parenteral support.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is the focus of Ironwood's presentation?
The presentation focuses on new diagnosis codes for short bowel syndrome patients.
When will Ironwood present their data?
Ironwood will present their data at Digestive Disease Week 2025.
Why is this data important?
This data aims to enhance understanding and treatment for patients dependent on parenteral support.